Chr. Hansen Holding A/S (CHYHY)

OTCMKTS: CHYHY · Delayed Price · USD
17.93
0.00 (0.00%)
Jan 13, 2023, 4:00 PM EST - Market closed
Market Cap 9.44B
Revenue (ttm) 1.35B
Net Income (ttm) 245.09M
Shares Out 526.41M
EPS (ttm) 0.47
PE Ratio 39.70
Forward PE 34.48
Dividend $1.01 (5.66%)
Ex-Dividend Date Nov 24, 2022
Volume 20,460
Open 17.87
Previous Close 17.93
Day's Range 17.82 - 17.97
52-Week Range 11.78 - 21.40
Beta 0.24
Analysts Hold
Price Target 18.95 (+5.69%)
Earnings Date Jan 12, 2023

About CHYHY

Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. It operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products ... [Read more]

Sector Materials
Founded 1874
Employees 3,834
Stock Exchange OTCMKTS
Ticker Symbol CHYHY
Full Company Profile

Financial Performance

In 2022, CHYHY's revenue was 1.22 billion, an increase of 13.05% compared to the previous year's 1.08 billion. Earnings were 225.10 million, a decrease of -73.37%.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for CHYHY stock is "Hold." The 12-month stock price forecast is $18.95, which is an increase of 5.69% from the latest price.

Price Target
$18.95
(5.69% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Chr. Hansen Holding A/S Interim Report Q1 2022/23

Statement by CEO Mauricio Graber: “The solid results for Q1 show the strength of our business model. Organic growth reached 10%, driven by both volume and pricing initiatives and EBIT b.s.i. increased...

3 weeks ago - GlobeNewsWire

Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S

NOVEMBER 23, 2022 – ANNOUNCEMENT NO. 11

2 months ago - GlobeNewsWire

Chr. Hansen Holding A/S - Major shareholder announcement from APG Asset Management N.V.

Company announcement no. 6/2022 August 2, 2022

6 months ago - GlobeNewsWire

Chr. Hansen Holding A/S Interim Report Q3 2021/22

Company announcement no. 05/2022

7 months ago - GlobeNewsWire

Chr. Hansen Holding A/S Interim Report Q2 2021/22

Company announcement no. 03/2022

11 months ago - GlobeNewsWire

Chr. Hansen Holding A/S Interim Report Q1 2021/22

January 13, 2022

1 year ago - GlobeNewsWire

Chr. Hansen Holding A/S - Manager's transactions

Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364

1 year ago - GlobeNewsWire

Chr. Hansen Holding A/S Interim Report Q3 2020/21

July 8, 2021

1 year ago - GlobeNewsWire

Extraordinary dividend

Company announcement No. 7

1 year ago - GlobeNewsWire

Chr. Hansen Holding A/S Interim report Q2 2020/21

Continued strong organic growth momentum leads to upwards narrowing of full-year organic growth guidance

1 year ago - GlobeNewsWire

Chr. Hansen Holding A/S Interim report Q1 2020/21

Company Announcement No. 01

2 years ago - GlobeNewsWire

Chr. Hansen Holding A/S Full-year report - Statement of results 2019/20

Company Announcement No. 23/2020

2 years ago - GlobeNewsWire

Chr. Hansen Holding A/S enters into a definitive agreement to divest its Natural Colors business to EQT

Chr. Hansen Holding A/S has today entered into an agreement to divest its Natural Colors business to the EQT IX Fund for a cash consideration of 800 EUR million on cash and debt free basis. The transa...

2 years ago - GlobeNewsWire

Chr. Hansen Holding A/S acquires Jennewein Biotechnologie GmbH to enter and lead the high-growth Human Milk Oligosaccharides market

Chr. Hansen Holding A/S (“Chr. Hansen”) has today entered into an agreement to acquire all of the shares of Jennewein Biotechnologie GmbH (“Jennewein”), which is a leading player in the Human Milk Oli...

2 years ago - GlobeNewsWire

UAS Laboratories LLC, a portfolio company of Lakeview Equity Partners, LLC, has been sold to Chr. Hansen Holding A/S

CHICAGO, July 28, 2020 /PRNewswire/ -- Lincoln International is pleased to announce that UAS Laboratories LLC, a portfolio company of Lakeview Equity Partners, LLC, has been sold to Chr. Hansen Holdin...

2 years ago - PRNewsWire

Chr. Hansen Holding A/S acquires UAS Laboratories LLC

Company Announcement No. 15/2020 - Chr. Hansen Holding A/S has today entered into an agreement with the owners of UAS Laboratories LLC (“UAS Labs”) to acquire 100% of the Wisconsin based B2B company s...

2 years ago - GlobeNewsWire